CD4 and neoplasm: A combination treatment (i.e., RT + Ch/γ-PGA NPs) synergistically disrupted a 4T1 tumor improvement, which resulted in a considerable early tumor growth and splenic depletion, decreased the percentage of splenic immune-suppressive myeloid cells, and increased the anti-tumor CD4+IFN-γ+ population.